Skip to content
Open menu Close menu

Reducing Irritants in Skin Products

Reducing Irritants in Skin Products

This KTP supported RB Healthcare Ltd to reduce the irritancy potential of their skin product formulation by developing a new in vitro (test-tube experiment) modelling strategy to understand how topical formulations can impact on healthy and compromised skin.

Project Outcomes

The partnership provided the company with the opportunity to acquire new skills and techniques in skin and hair-associated product development which resulted in a competitive advantage in the personal care field. They identified gaps and strategies relating to decision modelling methods and developed Standard Operating Procedures (SOPs) to guide future in vitro irritancy testing.

The University were able to gain new knowledge in human 3D epidermis, a greater understanding of toxicology issues relating to personal care products and ingredient insight for skin products formulation. Professor Des Tobin and colleagues are continuing to develop research relationships with the company.

Business Benefits

The KTP project brought the business into contact with a world class skin expert, Professor Des Tobin. His valuable knowledge has helped guide the company’s developments within and outside the scope of the project.” Scott Seville, Technology and Innovation Manager – Germ Protection and Personal Care RB Healthcare (UK) Ltd.

The project aligned perfectly with a recent shift in focus to the Health and Hygiene pillars, which are 2 of RB’s strategic pillars. RB aimed to improve its capabilities by increasing speed and lowering costs for in vitro skin irritancy testing methods. The KTP helped the business develop an understanding of the available capabilities and methods that they can apply to future new developments in those fields.

The KTP resulted in RB developing Standard Operating procedures (SOP’s) that will inform future in vitro testing techniques by guiding decisions on appropriate tests for the product and properties being studied. This knowledge will help RB reduce errors, chose appropriate business partners, and interpret test results to contribute to remaining at the forefront of a rapidly changing landscape of in vitro testing.